但此次许可协议显示,Celleron似乎非常看好emactuzumab的未来。Celleron计划将该药物用于弥漫性TGCT治疗。罗氏及其子公司基因泰克先前进行的研究显示,emactuzumab对该特定目标表现出非常令人鼓舞的疗效。在这项研究中,使用emactuzumab治疗的TGCT患者中有86%(24人)对该药有反应,68%的患者在开始治疗后6周内出现部分反应。
但此次许可协议显示,Celleron似乎非常看好emactuzumab的未来。Celleron计划将该药物用于弥漫性TGCT治疗。罗氏及其子公司基因泰克先前进行的研究显示,emactuzumab对该特定目标表现出非常令人鼓舞的疗效。在这项研究中,使用emactuzumab治疗的TGCT患者中有86%(24人)对该药有反应,68%的患者在开始治疗后6周内出现部分反应。
Emactuzumab has been evaluated in 2 phase 1 studies as a single agent and in combination with paclitaxel in patients with advanced solid tumors and dt-TGCT, and in combination with selicrelumab in patients with advanced solid tumors (Table 1). No MTD of emactuzumab was reached in phase ...
SummaryBackground Diffuse-type tenosynovial giant cell tumour (dt-GCT) of the soft tissue (alternatively known as pigmented villonodular synovitis), an orphan disease with unmet medical need, is characterised by an overexpression of colony-stimulating factor 1 (CSF1), and is usually caused by a ...